Ticker brief
JAGX
last close
·
1 day
·
14 days
·
mkt cap
·
signals 14d
6
authors 14d
3
No price history on file for this name (likely non-equity or unlisted) — the “since then” column below stays blank.
Sentiment — last 14 days
daily mean sentiment, 2026-06-21 → 2026-06-30 · now +0.20 (−1 bearish … +1 bullish)
Who spoke3
| author | grade | trader score | signals | mean sent |
|---|---|---|---|---|
| @AccesswireNews | C | · | 3 | +0.22 |
| @OzmosiHealth | C | · | 2 | +0.27 |
| @BiopharmIQ | B | · | 1 | +0.00 |
Recent signals6of 6 in 14d — receipts included
| date (PT) | author | sent | what they said | since then | receipt |
|---|---|---|---|---|---|
| 2026-06-30 | @OzmosiHealth | +0.20 | Presentation describes additional results evaluating crofelemer for pediatric intestinal failure. | · | tweet ↗ |
| 2026-06-25 | @AccesswireNews | +0.00 | Jaguar Health announces conversion of Series O convertible preferred stock. | · | tweet ↗ |
| 2026-06-23 | @OzmosiHealth | +0.35 | Jaguar completes submission of new animal drug application for full FDA approval. | · | tweet ↗ |
| 2026-06-23 | @AccesswireNews | +0.45 | Jaguar Health completes NADA submission for full FDA approval of Crofelemer. | · | tweet ↗ |
| 2026-06-22 | @AccesswireNews | +0.20 | Jaguar announces plan to explore strategic alternatives tied to targeted NDA filing. | · | tweet ↗ |
| 2026-06-21 | @BiopharmIQ | +0.00 | Biotech catalyst watchlist for Phase 2 and Phase 3 readouts in Q2/H1 2026. | · | tweet ↗ |
“Since then” = price move from the close on the signal's date (PT) to the latest close — what happened after they said it, not a backtest. A — means no trading session has closed since the signal yet. Sentiment is our extracted per-tweet score, −1…+1.